Hyperfractionated Radiotherapy with Concurrent Cisplatin/5-Fluorouracil for Locoregional Advanced Head and Neck Cancer: Analysis of 105 Consecutive Patients
Table 1
Patient characteristics at baseline ().
Number of patients (%)
Age
Age in years, mean (range)
58.5 (40.2–78.5)
<55 years
42 (40)
≥55 years
3 (60)
Sex
Female
21 (20)
Male
84 (80)
Race
Caucasian
90 (86)
African-American
15 (14)
Site
Oropharynxa
78 (74)
Hypopharynxb
15 (14)
Larynx
13 (12)
Stage
III
30 (29)
IV
75 (71)
Tumor classification (T)
T1
6 (6)
T2
36 (34)
T3
45 (43)
T4
18 (17)
Nodal status (N)
N0
14 (13)
N1
24 (23)
N2
56 (53)
N3
11 (10)
Histologic gradec
Well
5 (5)
Moderately
44 (42)
Poorly
45 (43)
Unknown
11 (10)
Smoking history
No
23 (22)
Yes
82 (78)
<20 PY
21 (20)
20–40 PY
21 (20)
40–60 PY
18 (17)
>60 PY
18 (17)
Amount unknown
4 (4)
Alcohol history
No
8 (8)
Yes
90 (86)
Social
26 (25)
Moderate
29 (28)
Heavy
35 (33)
Unknown
7 (7)
HPV statusd
Positive
25 (34)
Negative
20 (27)
Unavailable
32 (43)
Karnofsky Performance Status
≤70
9 (9)
80
29 (28)
90
31 (30)
100
27 (26)
Unknown
9 (9)
Pretreatment Hgb
<12 g/dl
26 (25)
≥12 g/dl
71 (68)
Unavailable
8 (8)
Self-reported weight loss
None or less than 10 lbs
28 (27)
Greater than 10 lbs
67 (64)
Unknown
10 (10)
PY: pack-year; HPV: human papillomavirus; Hgb: hemoglobin.
aOne patient presented with 2 primary cancers of the oropharynx.
bOne patient presented with synchronous primary cancer of the oropharynx and hypopharynx.
cIf the histologic grade was midway between well to moderately or moderately to poorly differentiated, the higher grade was chosen.
dFor tumors of oropharyngeal primary site only.
